# Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

> **NCT06585410** · PHASE3 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 369 (estimated)

## Conditions studied

- Cutaneous Squamous Cell Carcinoma (CSCC)

## Interventions

- **DRUG:** Cemiplimab
- **PROCEDURE:** Standard of care

## Key facts

- **NCT ID:** NCT06585410
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-02
- **Primary completion:** 2030-05-03
- **Final completion:** 2030-05-03
- **Target enrollment:** 369 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06585410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06585410, "Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06585410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*